Neurological Disease

p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators.

KSK67 is a high-affinity dual sigma-2 and histamine H3 receptor antagonist, with K_is of 3.2, 1531, 101 nM for H3 receptor, sigma-1, sigma-2 receptor respectively. KSK67 can be used for research of nociceptive and neuropathic pain.

ADH-353 can inhibit Aβ fibrillation and reduce Aβ-induced cytotoxicity in SH-SY5Y and N2a cells. ADH-353 can be used in Alzheimer's disease-related research.

G2-Peptide is a 3-O-sulfated heparan sulfate (3-OS HS) binder and antiviral agent. G2-Peptide blocks herpesvirus attachment, entry, cell-to-cell spread and syncytium formation, and reduces viral protein translocation. G2-Peptide exhibits antiviral activity against both HSV-1 and HSV-2. G2-Peptide inhibits neural activity and impairs synapse assembly. G2-Peptide can be used in the research of genital herpes, ocular herpes infection and keratitis.

Anti-APP/Amyloid beta Antibody (3D6) (murine version of Bapineuzumab) is an antibody targeting β-amyloid protein (Aβ) with free Asp1. Anti-APP/Amyloid beta Antibody (3D6) recognizes and binds to the amino acid epitope at positions 1-5 of β-amyloid protein carrying the free Asp1 residue. Anti-APP/Amyloid beta Antibody (3D6) can be used in research related to Alzheimer's disease.

JNJ-38893777 is an orally active and highly selective transient receptor potential vanilloid type 1 (TRPV1) channel antagonist. JNJ-38893777 inhibits neuronal hyperactivation and reduces inflammatory hyperalgesia. JNJ-38893777 is promising for research of migraine headaches, neuropathic and inflammatory pain.

Ciproxifan (FUB 359) hydrochloride is a potent, selective, orally bioavailable and competitive antagonist of histamine H₃-receptor, with an IC₅₀ of 9.2 nM. Ciproxifan hydrochloride displays low apparent affinity at other receptor subtypes. Ciproxifan hydrochloride can be used for the research of aging disorders and Alzheimer's disease.

5-HT2C agonist-5 (Compound 3A) is a 5-HT2C agonist (EC₅₀: <1 nM). 5-HT2C agonist-5 can be used for research of brain disorders.

COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC₅₀s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice.

Valerian Extract is a valerian extract. Valerian Extract has potential sedative and anxiolytic effects..

Sodium Channel inhibitor 4 is a sodium channel inhibitor.

Quetiapine-d₈ (hemifumarate) is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC₅₀ of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects.

AMG8380, an orally active and less active enantiomer of AMG8379, can serves as a negative control. AMG8380 inhibits human and mouse voltage-gated sodium channel NaV1.7 with IC₅₀s of 0.907 and 0.387 μM, respectively. AMG8380 blocks Tetrodotoxin (TTX)-sensitive native channels with an IC₅₀ of 2560 nM.

Imidazoleacetic acid (Standard) is the analytical standard of Imidazoleacetic acid (HY-113413). This product is intended for research and analytical applications. Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABA_A receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity.

OBHS is an estrogen receptor α (ERα) inhibitor. OBHS can also be used as a blowing agent.

β-Secretase substrate VI, fluorogenic is an EDANS and DABCYL double-labeled peptide，serves as a fluorescent substrate for BACE1(Em=360nm，Ex=528nm). β-Secretase substrate VI, fluorogenic can be used for BACE1 activity measurement and the enzyme activity level is directly proportional to the fluorescence reaction.

SR-1815 is a small molecule multi-kinase inhibitor. SR-1815, through mechanisms such as splicing regulation effectively restores the SynGAP protein to normal levels in the disease model with Syngap1 haploinsufficiency, thereby correcting the functional abnormalities at the synaptic and neuronal network levels caused by the deficiency of this gene. SR-1815 can be used for the study of brain diseases.

VU0361747 is a potent and selective positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4 PAM). VU0361737 has neuroprotective effect. VU0361737 significantly reverses Amphetamine-induced hyperlocomotion in vivo.

I2-IRs ligand-1 (Compound 12d) is an orally active and BBB-penetrable compound. I2-IRs ligand-1 has a high affinity for imidazoline I₂ receptors (I₂-IRs) (pK_i: 9.98). I2-IRs ligand-1 can improve cognitive impairment in senescent mice and exhibits analgesic, anti-inflammatory, and neuroprotective activities. I2-IRs ligand-1 can be used for the research of Alzheimer's disease and related pain disorders.

AChE-IN-94 is an orally active and blood-brain barrier penetrable AChE inhibitor with an IC₅₀ of 0.40 μM and K_i of 0.28 μM. AChE-IN-94 prevents self-induced and AChE-mediated Aβ_1-42 aggregation. AChE-IN-94 alleviates cognitive/memory deficits in Scopolamine (HY-N0296)-induced amnesic model. AChE-IN-94 can be used for the study of Alzheimer's disease (AD).